Early Screening for Type 1 Diabetes in Children With Affected Relatives
Screens children with a close relative with type 1 diabetes for early signs of disease.
Plain-language title generated from the registry record
Registry title: Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF)
Key facts
- Where
- Dammam, Jeddah, and Riyadh, Saudi ArabiaSee the 4 sites
Where in Saudi Arabia
- Imam Abdulrahman Bin Faisal University - Site Number: 05Dammam, Saudi ArabiaTaking people
- King Abdulaziz Medical City, National Guard Hospital, Jeddah - Site Number: 01Jeddah, Saudi ArabiaTaking people
- King Fahd Medical City - Site Number: 03Riyadh, Saudi ArabiaTaking people
- King Faisal Specialist Hospital & Research Centre - Site Number: 02Riyadh, Saudi ArabiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sanofi
- Trial code
- NCT07038473
- Record updated
- 23 October 2026
- Original description
The aim of this research is to identify pre-symptomatic Type 1 Diabetes (T1D) in young children and adolescents who have first degree relatives with T1D. This protocol has been developed to address the growing need for standardized T1D screening, monitoring, and data collection in alignment with international recommendations. The study's estimated duration is 13 months and will consist of two visits: Visit 1 (screening visit) and Visit 2 (confirmatory visit).Read full original descriptionShow less
Islet Autoantibody Early Detection in At-risk Children/Adolescents to Predict Type 1 Diabetes: a Cohort Study in Gulf Countries
The aim of this research is to identify pre-symptomatic Type 1 Diabetes (T1D) in young children and adolescents who have first degree relatives with T1D. This protocol has been developed to address the growing need for standardized T1D screening, monitoring, and data collection in alignment with international recommendations. The study's estimated duration is 13 months and will consist of two visits: Visit 1 (screening visit) and Visit 2 (confirmatory visit).
Inclusion: Children and adolescents, age 1.5 years to 18 years; First degree relatives of T1D probands; Parent or legal guardian signing an informed consent.
Exclusion: Have a previous history of being treated with insulin; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial; Known diabetes of any kind (type 1, type 2, Maturity Onset Diabetes of the Young - MODY); Already developed clinical overt T1D.